ABSTRAL SUBLINGUAL TABLET 300 MCG

RECIPHARM LEGANÉS S.L.U. (SPAIN)🇸🇬 Health Sciences Authority

Approval Date: Jan 6, 2017
Approval ID: 307fbde203516323
Company: RECIPHARM LEGANÉS S.L.U. (SPAIN)
Type: Therapeutic

Approval Details

Approval Id: 307fbde203516323
Drug Name: ABSTRAL SUBLINGUAL TABLET 300 MCG
Product Name: ABSTRAL SUBLINGUAL TABLET 300 MCG
Approval Number: SIN15149P
Approval Date: 2017-01-06
Registrant: A. MENARINI SINGAPORE PTE. LTD.
Licence Holder: A. MENARINI SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET
Dosage: 4.2 Posology and method of administration Abstral should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain. Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. Method of administration: Abstral sublingual tablets should be administered directly under the tongue at the deepest part. Abstral sublingual tablets should not be swallowed, but allowed to completely dissolve in the sublingual cavity without chewing or sucking. Patients should be advised not to eat or drink anything until the sublingual tablet is completely dissolved. In patients who have a dry mouth water may be used to moisten the buccal mucosa before taking Abstral. Dose titration: The objective of dose titration is to identify an optimal maintenance dose for ongoing treatment of breakthrough pain episodes. This optimal dose should provide adequate analgesia with an acceptable level of adverse reactions. The optimal dose of Abstral will be determined by upward titration, on an individual patient basis. Several doses are available for use during the dose titration phase. The initial dose of Abstral used should be 100 micrograms, titrating upwards as necessary through the range of available dosage strengths. Patients should be carefully monitored until an optimal dose is reached. Switching from other fentanyl containing products to Abstral must not occur at a 1:1 ratio because of different absorption profiles. If patients are switched from another fentanyl containing product, a new dose titration with Abstral is required. The following dose regimen is recommended for titration, although in all cases the physician should take into account the clinical need of the patient, age and concomitant illness. All patients must start therapy with a single 100 microgram sublingual tablet. If adequate analgesia is not obtained within 30 minutes of administration of a single sublingual tablet, a supplemental (second) 100 microgram sublingual tablet may be administered. If adequate analgesia is not obtained within 30 minutes of the first dose an increase in dose to the next higher tablet strength should be considered for the next episode of breakthrough pain (Refer to figure below). Dose escalation should continue in a stepwise manner until adequate analgesia with tolerable adverse reactions is achieved. The dose strength for the supplemental (second) sublingual tablet should be increased from 100 to 200 micrograms at doses of 400 micrograms and higher. This is illustrated in the schedule below. No more than two (2) doses should be administered for a single episode of breakthrough pain during this titration phase. <img src="/TGIF/Abstral-Flowchart1.png" alt="Abstral Dosage Flowchart 1" /> <img src="/TGIF/Abstral-Table1.png" alt="Abstral Dosage Table 1" /> If adequate analgesia is achieved at the higher dose, but undesirable effects are considered unacceptable, an intermediate dose (using the 100 microgram sublingual tablet where appropriate) may be administered. During titration, patients can be instructed to use multiples of 100 microgram tablets and/or 200 microgram tablets for any single dose. No more than four (4) tablets should be used at any one time. The efficacy and safety of doses higher than 800 micrograms have not been evaluated in clinical studies in patients. In order to minimise the risk of opioid-related adverse reactions and to identify the appropriate dose, it is imperative that patients be monitored closely by health professionals during the titration process. During titration patients should wait at least 2 hours before treating another episode of breakthrough pain with Abstral. Maintenance therapy: Once an appropriate dose has been established, which may be more than one tablet, patients should be maintained on this dose and should limit consumption to a maximum of four Abstral doses per day. During the maintenance period patients should wait at least 2 hours before treating another episode of breakthrough pain with Abstral. Dose re-adjustment: If the response (analgesia or adverse reactions) to the titrated Abstral dose markedly changes, an adjustment of dose may be necessary to ensure that an optimal dose is maintained. If more than four episodes of breakthrough pain are experienced per day over a period of more than four consecutive days, then the dose of the long acting opioid used for persistent pain should be re-evaluated. If the long acting opioid or dose of long acting opioid is changed the Abstral dose should be re-evaluated and re-titrated as necessary to ensure the patient is on an optimal dose. It is imperative that any dose re-titration of any analgesic is monitored by a health professional. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Treatment duration and goals Before initiating treatment with Abstral, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Abstral should not be used longer than necessary. Discontinuation of therapy: Abstral should be discontinued immediately if the patient no longer experiences breakthrough pain episodes. The treatment for the persistent background pain should be kept as prescribed. If discontinuation of all opioid therapy is required, the patient must be closely followed by the doctor in order to avoid the possibility of abrupt withdrawal effects. Use in children and adolescents: Abstral must not be used in patients less than 18 years of age due to a lack of data on safety and efficacy. Use in older people: Dose titration needs to be approached with particular care and patients observed carefully for signs of fentanyl toxicity (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Use in patients with renal and hepatic impairment Patients with kidney or liver dysfunction should be carefully observed for signs of fentanyl toxicity during the Abstral titration phase (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Route Of Administration: SUBLINGUAL
Indication Info: 4.1 Therapeutic indications Management of breakthrough pain in adult patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Patients without maintenance opioid therapy as there is an increased risk of respiratory depression. Severe respiratory depression or severe obstructive lung conditions. Treatment of acute pain other than breakthrough pain. Patients being treated with medicinal products containing sodium oxybate.
Atc Code: N02AB03
Atc Item Name: fentanyl
Pharma Manufacturer Name: A. MENARINI SINGAPORE PTE. LTD.

Active Ingredients

FENTANYL CITRATE (MICRONIZED) 471.3 μg eqv. FENTANYL

300 µg

FENTANYL CITRATE (MICRONIZED) 471.3 μg eqv. FENTANYL

300 µg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 6, 2017

Approval ID

307fbde203516323

Type

Therapeutic

Back to HSA Approvals